4. Xie LQ, Wang X. C-reactive protein and
atherosclerosis. Sheng Li Ke Xue Jin Zhan. 2004
Apr;35(2):113-8.
5. Verma S.
C-reactive protein incites atherosclerosis. Can J Cardiol. 2004
Aug;20 Suppl B29B-31B.
6. Stochmal E,
Szurkowska M, Czarnecka D, et al. Association of coronary
atherosclerosis with insulin resistance in patients with impaired
glucose tolerance. Acta Cardiol. 2005 Jun;60(3):325-31.
7. Sharrett AR,
Patsch W, Sorlie PD, et al. Associations of lipoprotein
cholesterols, apolipoproteins A-I and B, and triglycerides with
carotid atherosclerosis and coronary heart disease. The
Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler
Thromb. 1994 Jul;14(7):1098-104.
8. Muis MJ, Bots
ML, Bilo HJ, et al. High cumulative insulin exposure: a risk factor
of atherosclerosis in type 1 diabetes? Atherosclerosis. 2005
Jul;181(1):185-92.
9. Malkin CJ,
Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a
protective factor against atherosclerosis—immunomodulation and
influence upon plaque development and stability. J Endocrinol. 2003
Sep;178(3):373-80.
10. Howes PS,
Zacharski LR, Sullivan J, Chow B. Role of stored iron in
atherosclerosis. J Vasc Nurs. 2000 Dec;18(4):109-14.
11. Jones RD,
Nettleship JE, Kapoor D, Jones HT, Channer KS. Testosterone and
atherosclerosis in aging men: purported association and clinical
implications. Am J Cardiovasc Drugs. 2005;5(3):141-54.
12. de Valk B,
Marx JJ. Iron, atherosclerosis, and ischemic heart disease. Arch
Intern Med. 1999 Jul 26;159(14):1542-8.
13. Drexel H,
Amann FW, Beran J, et al. Plasma triglycerides and three lipoprotein
cholesterol fractions are independent predictors of the extent of
coronary atherosclerosis. Circulation. 1994 Nov;90(5):2230-5.
14. Chau LY.
Iron and atherosclerosis. Proc Natl Sci Counc Repub China B. 2000
Oct;24(4):151-5.
15. Bolad I,
Delafontaine P. Endothelial dysfunction: its role in hypertensive
coronary disease. Curr Opin Cardiol. 2005 Jul;20(4):270-4.
16. Chakraphan
D, Sridulyakul P, Thipakorn B, et al. Attenuation of endothelial
dysfunction by exercise training in STZ-induced diabetic rats. Clin
Hemorheol Microcirc. 2005;32(3):217-26.
17. Harvey PJ,
Picton PE, Su WS, et al. Exercise as an alternative to oral estrogen
for amelioration of endothelial dysfunction in postmenopausal women.
Am Heart J. 2005 Feb;149(2):291-7.
18. Hink U,
Tsilimingas N, Wendt M, Munzel T. Mechanisms underlying endothelial
dysfunction in diabetes mellitus: therapeutic implications. Treat
Endocrinol. 2003;2(5):293-304.
19. Lteif AA,
Han K, Mather KJ. Obesity, insulin resistance, and the metabolic
syndrome: determinants of endothelial dysfunction in whites and
blacks. Circulation. 2005 Jul 5;112(1):32-8.
20. Newby DE,
McLeod AL, Uren NG, et al. Impaired coronary tissue plasminogen
activator release is associated with coronary atherosclerosis and
cigarette smoking: direct link between endothelial dysfunction and
atherothrombosis. Circulation. 2001 Apr 17;103(15):1936-41.
21. Panus C,
Mota M, Vladu D, Vanghelie L, Raducanu CL. The endothelial
dysfunction in diabetes mellitus. Rom J Intern Med.
2003;41(1):27-33.
22. Papamichael
CM, Aznaouridis KA, Stamatelopoulos KS, et al. Endothelial
dysfunction and type of cigarette smoked: the impact of ‘light’
versus regular cigarette smoking. Vasc Med. 2004 May;9(2):103-5.
23. Suvorava T,
Lauer N, Kojda G. Physical inactivity causes endothelial dysfunction
in healthy young mice. J Am Coll Cardiol. 2004 Sep 15;44(6):1320-7.
24. Toikka JO,
Ahotupa M, Viikari JS, et al. Constantly low HDL-cholesterol
concentration relates to endothelial dysfunction and increased in
vivo LDL-oxidation in healthy young men. Atherosclerosis. 1999 Nov
1;147(1):133-8.
25. Vakkilainen
J, Makimattila S, Seppala-Lindroos A, et al. Endothelial dysfunction
in men with small LDL particles. Circulation. 2000 Aug
15;102(7):716-21.
26. Apetrei E,
Ciobanu-Jurcut R, Rugina M, Gavrila A, Uscatescu V. C-reactive
protein, prothrombotic imbalance and endothelial dysfunction in
acute coronary syndromes without ST elevation. Rom J Intern Med.
2004;42(1):95-102.
27. Kunes P.
C-reactive protein in the pathogenesis of atherosclerosis: advantage
and pitfalls of the “Mainz hypothesis.” Cas Lek Cesk.
2005;144(1):25-31.
28. Targher G,
Bertolini L, Zoppini G, Zenari L, Falezza G. Increased plasma
markers of inflammation and endothelial dysfunction and their
association with microvascular complications in Type 1 diabetic
patients without clinically manifest macroangiopathy. Diabet Med.
2005 Aug;22(8):999-1004.
29. Sainani GS,
Sainani R. Homocysteine and its role in the pathogenesis of
atherosclerotic vascular disease. J Assoc Physicians India. 2002
May;50 Suppl16-23.
30. Drouet L,
Bal dit SC. Is fibrinogen a predictor or a marker of the risk of
cardiovascular events? Therapie. 2005 Mar;60(2):125-36.
31. Caballero
AE, Arora S, Saouaf R, et al. Microvascular and macrovascular
reactivity is reduced in subjects at risk for type 2 diabetes.
Diabetes. 1999 Sep;48(9):1856-62.
32. Ceriello A.
Hyperglycaemia: the bridge between non-enzymatic glycation and
oxidative stress in the pathogenesis of diabetic complications.
Diabetes Nutr Metab. 1999 Feb;12(1):42-6.
33. Cubeddu LX,
Hoffmann IS. Insulin resistance and upper-normal glucose levels in
hypertension: a review. J Hum Hypertens. 2002 Mar;16 Suppl 1S52-5.
34. Nowak A,
Stankiewicz W, Szczesniak L, Korman E. Glucosamine in the blood
serum of young people with diabetes mellitus type 1. Endokrynol
Diabetol Chor Przemiany Materii Wieku Rozw. 1999;5(2):97-101.
35. Steinbaum
SR. The metabolic syndrome: an emerging health epidemic in women.
Prog Cardiovasc Dis. 2004 Jan;46(4):321-36.
36. Woodman RJ,
Chew GT, Watts GF. Mechanisms, significance and treatment of
vascular dysfunction in type 2 diabetes mellitus: focus on
lipid-regulating therapy. Drugs. 2005;65(1):31-74.
37. Brandes RP,
Fleming I, Busse R. Endothelial aging. Cardiovasc Res. 2005 May
1;66(2):286-94.
38. Kravchenko
J, Goldschmidt-Clermont PJ, Powell T, et al. Endothelial progenitor
cell therapy for atherosclerosis: the philosopher’s stone for an
aging population? Sci Aging Knowledge Environ. 2005 Jun
22;2005(25):e18.
39. Rubanyi GM.
The role of endothelium in cardiovascular homeostasis and diseases.
J Cardiovasc Pharmacol. 1993;22 Suppl 4:S1-14.
40. Available
at:http://www.medreviews.com/ pdfs/articles/RIU_5Suppl7_S21.pdf.
Accessed April 20, 2005.
41. Available
at:
http://www.escardio.org/knowledge/cardiology_practice/
ejournal_vol1/Vol1_no16.htm.
Accessed April 20,
2005.
42. Cavallini G, Caracciolo S,
Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen
administration in the treatment of sexual dysfunction, depressed
mood, and fatigue associated with male aging. Urology. 2004
Apr;63(4):641-6.
43. Vermeulen RC, Scholte HR.
Exploratory open label, randomized study of acetyl- and
propionylcarnitine in chronic fatigue syndrome. Psychosom Med. 2004
Mar;66(2):276-82.
44. Bertelli A, Conte A, Ronca G,
Segnini D, Yu G. Protective effect of propionyl carnitine against
peroxidative damage to arterial endothelium membranes. Int J Tissue
React. 1991;13(1):41-3.
45. Amico-Roxas M, Caruso A, Cutuli
VM, de Bernardis E, Leonardi G. Inhibitory effects of
propionyl-L-carnitine on plasma extravasation induced by irritants
in rodents. Drugs Exp Clin Res. 1993;19(5):213-7.
46. Bertelli A, Conte A, Palmieri
L, et al. Effect of propionyl carnitine on energy charge and adenine
nucleotide content of cardiac endothelial cells during hypoxia. Int
J Tissue React. 1991;13(1):37-40.
47. Wiseman LR, Brogden RN.
Propionyl-L-carnitine. Drugs Aging. 1998 Mar;12(3):243-8.
48. Ferrari R, Merli E, Cicchitelli
G, et al. Therapeutic effects of L-carnitine and
propionyl-L-carnitine on cardiovascular diseases: a review. Ann NY
Acad Sci. 2004 Nov;1033:79-91.
49. Hiatt WR. Carnitine and
peripheral arterial disease. Ann NY Acad Sci. 2004 Nov;1033:92-8.
50. Anand I, Chandrashekhan Y, De
Giuli F, et al. Acute and chronic effects of propionyl-L-carnitine
on the hemodynamics, exercise capacity, and hormones in patients
with congestive heart failure. Cardiovasc Drugs Ther. 1998
Jul;12(3):291-9.
51. Sayed-Ahmed MM, Salman TM,
Gaballah HE, et al. Propionyl-L-carnitine as protector against
adriamycin-induced cardiomyopathy. Pharmacol Res. 2001
Jun;43(6):513-20.
52. Bartels GL, Remme WJ, Pillay M,
Schonfeld DH, Kruijssen DA. Effects of L-propionylcarnitine on
ischemia-induced myocardial dysfunction in men with angina pectoris.
Am J Cardiol. 1994 Jul 15;74(2):125-30.
53. Spagnoli LG, Orlandi A, Marino
B, et al. Propionyl-L-carnitine prevents the progression of
atherosclerotic lesions in aged hyperlipemic rabbits.
Atherosclerosis. 1995 Apr 7;114(1):29-44.
54. Barker GA, Green S, Askew CD,
Green AA, Walker PJ. Effect of propionyl-L-carnitine on exercise
performance in peripheral arterial disease. Med Sci Sports Exerc.
2001 Sep;33(9):1415-22.
55. Brevetti G, Perna S, Sabba C,
et al. Superiority of L-propionylcarnitine vs L-carnitine in
improving walking capacity in patients with peripheral vascular
disease: an acute, intravenous, double-blind, cross-over study. Eur
Heart J. 1992 Feb;13(2):251-5.
56. Kaiser KP, Feinendegen LE.
Planar scintigraphy versus PET in measuring fatty acid metabolism of
the heart. Herz. 1987 Feb;12(1):41-50.
57. Torielli L, Conti F, Cinato E,
et al. Alterations in energy metabolism of hypertrophied rat
cardiomyocytes: influence of propionyl-L-carnitine. J Cardiovasc
Pharmacol. 1995 Sep;26(3):372-80.
58. Bueno R, Alvarez de Sotomayor
M, Perez-Guerrero C, et al. L-carnitine and propionyl-L-carnitine
improve endothelial dysfunction in spontaneously hypertensive rats:
Different participation of NO and COX-products. Life Sci. 2005 Jun
13.
59. Broderick TL, Haloftis G,
Paulson DJ. L-propionylcarnitine enhancement of substrate oxidation
and mitochondrial respiration in the diabetic rat heart. J Mol Cell
Cardiol. 1996 Feb;28(2):331-40.
60. Brevetti G, Perna S, Sabba C,
Martone VD, Condorelli M. Propionyl-L-carnitine in intermittent
claudication: double-blind, placebo-controlled, dose titration,
multicenter study. J Am Coll Cardiol. 1995 Nov 15;26(6):1411-16.
61. Rabini RA, Petruzzi E,
Staffolani R, et al. Diabetes mellitus and subjects’ ageing: a study
on the ATP content and ATP-related enzyme activities in human
erythrocytes. Eur J Clin Invest. 1997 Apr;27(4):327-32.
62. Kichenin K, Decollogne S,
Angignard J, Seman M. Cardiovascular and pulmonary response to oral
administration of ATP in rabbits. J Appl Physiol. 2000
Jun;88(6):1962-8.
63. Kichenin K, Seman M. Chronic
oral administration of ATP modulates nucleoside transport and purine
metabolism in rats. J Pharmacol Exp Ther. 2000 Jul;294(1):126-33.
64. US patent 5,049,372. US patent
5,227,371.
65. Van Aken H, Puchstein C, Fitch
W, Graham DI. Haemodynamic and cerebral effects of ATP-induced
hypotension. Br J Anaesth. 1984 Dec;56(12):1409-16.
66. Rosenmeier JB, Hansen J,
Gonzalez-Alonso J. Circulating ATP-induced vasodilatation overrides
sympathetic vasoconstrictor activity in human skeletal muscle. J
Physiol. 2004 Jul 1;558(Pt 1):351-65.
67. Gonzalez-Alonso J, Olsen DB,
Saltin B. Erythrocyte and the regulation of human skeletal muscle
blood flow and oxygen delivery: role of circulating ATP. Circ Res.
2002 Nov 29;91(11):1046-55.
68. Ellsworth ML, Forrester T,
Ellis CG, Dietrich HH. The erythrocyte as a regulator of vascular
tone. Am J Physiol. 1995 Dec;269(6 Pt 2):H2155-161.
69. Sprague RS, Stephenson AH,
Ellsworth ML, Keller C, Lonigro AJ. Impaired release of ATP from red
blood cells of humans with primary pulmonary hypertension. Exp Biol
Med (Maywood.). 2001 May;226(5):434-9.
70. Sprague RS, Ellsworth ML,
Stephenson AH, Kleinhenz ME, Lonigro AJ. Deformation-induced ATP
release from red blood cells requires CFTR activity. Am J Physiol.
1998 Nov;275(5 Pt 2):H1726-32.
71. Kitakaze M, Minamino T, Node K,
et al. Adenosine and cardioprotection in the diseased heart. Jpn
Circ J. 1999 Apr;63(4):231-43.
